HeartX, powered by HealthTech Arkansas and MedAxiom, along with seven Arkansas healthcare providers — Arkansas Children’s Hospital, Arkansas Heart Hospital, Baptist Health, CHI St. Vincent, Conway Regional Health System, St. Bernards Healthcare, and Washington Regional Medical Center — have selected the five startup healthcare companies that will participate in the 2022 accelerator program. HeartX is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market.
The five companies selected for the 2022 HeartX program are:
Acorai, Helsingborg, Sweden
Acorai produces a device for heart failure management through non-invasive intracardiac pressure monitoring. It is handheld and uses multi-modal sensor technologies and a proprietary machine learning system based on unique insights into flow and pressure dynamics.
Echo IQ, Sydney, Australia
Echo IQ uses AI to support the diagnosis of structural heart conditions. The AI helps to identify at-risk patients classified by guidelines and patients who have a risk phenotype but fall outside of traditional guidelines.
iCardio.ai, Los Angeles, California
The iCardio.ai Brain is an AI software that can intake an entire echocardiogram and produce a full cardiologist report. The software is trained to recognize multiple pathologies and can be used to more efficiently identify at-risk patients, increase visibility into abnormalities, and increase the accuracy and consistency of diagnosis.
MediWhale, Seoul, South Korea
MediWhale has created Reti-CVD, an AI analytic tool that uses retinal images to identify people with high CVD risk. Developed using large global epidemiological databases, the analytic identifies subtle features in retinal vasculature for precision CVD risk calculation.
SafeBeat Rx, Chico, California
SafeBeat Rx is an at-home kit that includes machine-learning software which automates ECG measurements and recommends drug dosing to physicians, as well as FDA-approved devices (mobile ECG; mobile cardiac telemetry; wearable cardioverter defibrillator). This kit enables at-home initiation of the most efficacious antiarrhythmic drugs, replacing a 3-day hospitalization.
HeartX is hosting an event on November 1, 2022, at Arkansas Heart Hospital Encore Medical Center to introduce the five startup companies selected for the 2022 accelerator program.
“The cardiovascular industry is steeped in innovation and technology, which has resulted in impressive advancements in care delivery for patients around the world. MedAxiom and HealthTech Arkansas formed HeartX to accelerate cardiovascular innovation and bring new solutions to the market by connecting early-stage companies with healthcare delivery networks. The HeartX 2022 cohort companies share MedAxiom’s mission of transforming cardiovascular care and improving heart health. We look forward to working closely with these innovators to deliver new options to cardiovascular organizations and patients,” said Joe Sasson, PhD, MedAxiom’s chief commercial officer and executive vice president of Ventures.
“We are excited to reveal the new cohort and introduce them to Arkansas and the powerful teams available to them at all of our healthcare provider partners around the state,” said Jeff Stinson, director of HealthTech Arkansas. “This year’s companies are exceptionally strong, due in no small part to MedAxiom’s contributions as our program partner. We’re proud of our role in healthcare innovation as the only program in the country that guarantees hospital pilot projects for early-stage companies, which produces exceptionally accomplished cohorts.”
Representatives from each of the seven healthcare providers interviewed applicants and selected companies with technologies that have the potential to advance cardiovascular innovation and cardiac care at their respective organizations. The cohort will participate in a program that provides them the opportunity to build solutions specifically identified by Arkansas cardiovascular healthcare providers as areas of opportunity within their organizations. Each company will receive $150,000 of investment capital as well as complete and total access to clinicians and administrators while executing their pilot projects with Arkansas hospitals.